CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics
<!-- Name:DistributionId Value:8754581 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
KemPharm
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research…
CELEBRATION, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a rare disease therapeutics company focused on the development of…
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating…
SDX administered at single doses of 80 mg and 200 mg was well-tolerated CELEBRATION, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company),…
KemPharm to Present at Multiple Upcoming Investor Conferences
CELEBRATION, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development…
KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference
CELEBRATION, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,…
KemPharm Completes KP1077 Pre-IND Meeting Process with FDA
KemPharm Positioned to Submit IND Application for KP1077 for Idiopathic Hypersomnia by Mid-2022 CELEBRATION, Fla., Feb. 23, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a…
KemPharm Named 2021 David J. Gury Company of the Year by BioFlorida
CELEBRATION, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,…
AZSTARYS®, An Innovative ADHD Treatment Developed by KemPharm, to be Featured in a…
Pharmacokinetic data from two clinical studies of AZSTARYS demonstrated its rapid onset of action and long duration of effect CELEBRATION, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) --…
KemPharm Announces Research Involving AZSTARYS® and Serdexmethylphenidate to be…
CELEBRATION, Fla., Oct. 20, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,…
KemPharm to Present at the Benzinga Healthcare Small Cap Conference
CELEBRATION, Fla., Sept. 27, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,…